RPCA
AXDX icon

Running Point Capital Advisors’s Accelerate Diagnostics AXDX Stock Holding History

Running Point Capital Advisors’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,000
Closed -$15K – 217
2022
Q3 		$15K Hold
1,000
– – 0.01% 190
2022
Q2 		$10K Hold
1,000
– – 0.01% 203
2022
Q1 		$14K Buy
+1,000
New +$28.5K 0.01% 194

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Running Point Capital Advisors's AXDX Position: Q4 2022 in Review

Running Point Capital Advisors sold out of Accelerate Diagnostics (AXDX) in Q4 2022, closing a stake of 1,000 shares — an estimated $15K sold.

Running Point Capital Advisors first reported a position in AXDX in Q1 2022 and held it in 3 quarters. The position peaked at $15K in Q3 2022. 73 funds tracked by Wall St. Rank hold AXDX as of Q4 2022.

  • Running Point Capital Advisors reported no remaining Accelerate Diagnostics position as of Q4 2022 after selling out during the quarter.
  • Running Point Capital Advisors sold 1,000 Accelerate Diagnostics shares in Q4 2022, an estimated $15K.
  • Running Point Capital Advisors first reported a position in Accelerate Diagnostics in Q1 2022 and held it in 3 quarters.
  • Running Point Capital Advisors's Accelerate Diagnostics position peaked at $15K in Q3 2022.
  • 73 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2022.

Based on Running Point Capital Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.